Within melanomas, differentiated melanocytic cells are sensitive to BRAF and ERK inhibitors, while dedifferentiated cells that have lost their lineage markers (SOX10 and MITF) are drug-resistant [132,133]. This evidence concerns the gene MAPK1 and melanoma.